C4X Discovery Holdings PLC Board Appointment (9566V)
April 20 2021 - 01:00AM
UK Regulatory
TIDMC4XD
RNS Number : 9566V
C4X Discovery Holdings PLC
20 April 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Board Changes
C4X Discovery appoints Simon Harford as Non-Executive
Director
GSK and Eli Lilly industry financial veteran further strengthens
Board
20 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, today announces the appointment
of Simon Harford as Non-Executive Director with immediate
effect.
Simon joins C4XD with more than 30 years of significant
financial and investor relations expertise in global pharmaceutical
companies. Simon is currently CFO at Albireo Pharma Inc., a
NASDAQ-listed biotech company where he has raised more than $200
million in equity financing and was previously CFO of Parexel
International Inc., a global clinical research organisation, which
was acquired by private equity in 2017. Prior to this, Simon held
various financial leadership roles at GSK, including SVP Finance,
Global Pharmaceuticals. During his tenure, he was responsible for
finance in all pharmaceutical markets globally and was a member of
the Global Pharmaceutical Operations Committee. Simon also held key
financial management roles at Eli Lilly and Company over two
decades including Vice President and Controller, CFO and Executive
Director Finance for Europe, Middle East and Africa (EMEA) and led
the global investor relations function as Executive Director of
Investor Relations. He also received the Lilly, Chairman's Ovation
Award 2004 for outstanding achievement to Lilly.
Eva-Lotta Allan, Chairman of C4X Discovery, said: "Simon brings
a wealth of global pharmaceutical expertise across key financial
markets, including the US where he is based. His deep understanding
of global pharmaceutical financial strategy will be invaluable as
we continue to grow C4XD and expedite major out-licensing deals
such as our recent deals with Sanofi and Indivior. We welcome Simon
to the Board and look forward to working closely with him."
Simon Harford, incoming Non-Executive Director, added: "I am
delighted to be joining the C4XD Board at this stage of the
Company's development. C4XD has made great progress in the
execution of its strategy, which the recent deal with Sanofi
further validates. The Company's technologies are able to deliver
high quality and differentiated drug candidates for development by
pharma and biotech companies and I look forward to working with the
Board to continue growing the Company and delivering shareholder
value."
In accordance with Rule 17 and Schedule Two paragraph (g) of the
AIM Rules for Companies, additional information for Simon Nicolas
Reade Harford, aged 60, is set out below:
Current Directorships Previous Directorships (last
5 years)
N/A Liquent, Inc
PAREXEL International Corporation
As of the date of this announcement, Simon Harford holds no
ordinary shares in the capital of the Company.
There is no further information to disclose in respect of these
appointments under Rule 17 and Schedule 2 paragraph (g) of the AIM
Rules.
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
neurodegeneration, oncology and addictive disorders . Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio. For more information visit
us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAILMPTMTIBBAB
(END) Dow Jones Newswires
April 20, 2021 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Feb 2024 to Mar 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Mar 2023 to Mar 2024